Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	17.35B
Revenue (ttm)	6.00B
Net Income (ttm)	725.80M
Shares Out	501.47M
EPS (ttm)	1.52
PE Ratio	22.77
Forward PE	n/a
Dividend	0.55 (1.58%)
Ex-Dividend Date	Jul 11, 2025

Volume	1,282,158
Average Volume	1,483,169
Open	34.40
Previous Close	34.00
Day's Range	34.20 - 34.60
52-Week Range	24.33 - 39.80
Beta	-0.03
RSI	49.17
Earnings Date	Nov 11, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2024, Synmosa Biopharma's revenue was 5.55 billion, an increase of 7.96% compared to the previous year's 5.14 billion. Earnings were 684.68 million, an increase of 15.11%.